|
Getting your Trinity Audio player ready...
|
Fidson Healthcare Plc delivered its strongest half-year earnings on record in 2025, nearly quadrupling profit after tax. But a closer look at its unaudited financial statements reveals that the impressive numbers are being underpinned by a high-risk strategy of extending significant credit to distributors and hospitals, while simultaneously leaning on regional expansion to consolidate its position in Nigeria’s pharmaceutical market.
The company’s results for the six months ended June show revenue rising 68 percent year-on-year to N62.64 billion, up from N37.25 billion in the first half of 2024. Profit after tax jumped 298 percent to N6.02 billion, compared with N1.51 billion a year earlier, while gross profit advanced 70 percent to N25.71 billion.
Fidson maintained a 41 percent gross margin, a notable feat in a sector where rising input costs and inflationary pressures often erode profitability.
Operating profit rose 177 percent to N12.16 billion, reflecting management’s ability to scale revenue faster than expenses despite administrative costs nearly doubling and finance charges climbing by half. The results also benefited from a sharp decline in foreign exchange losses, which dropped to N2.08 billion from N4.39 billion a year earlier, offering much-needed relief in a year marked by naira volatility.
But beneath these headline figures, the drug maker’s balance sheet shows signs of strain from its pursuit of growth.
Trade receivables more than tripled in six months, swelling current assets to N58.81 billion as at June 2025 from N37.4 billion at year-end 2024. Prepayments also rose, suggesting the company is committing more cash upfront to secure raw materials and services.
By extending large volumes of credit, Fidson is effectively financing its large distributors, hospitals and pharmacies as a way of securing market share. In the short term, this strategy has supported sales expansion and helped the company penetrate deeper into regional markets. But it also exposes Fidson to delayed collections, with the risk that profits booked on paper do not translate into liquidity.
The strain is evident in cash flow. Despite delivering record profits, Fidson’s net cash from operating activities slipped into negative territory in H1 2025. The divergence between profitability and actual cash generation is a red flag, particularly in Nigeria’s high-interest-rate environment, where short-term financing is costly and credit recovery can be uncertain.
The liabilities side of the balance sheet further highlights the risks of Fidson’s expansion drive. Current liabilities increased 16 percent to N45.87 billion in six months, with interest-bearing borrowings more than doubling and trade payables jumping by nearly 90 percent. This reliance on both lenders and suppliers suggests the company is stretching external financing channels to keep growth on track.
While this approach signals confidence in sustained demand, it also increases exposure to refinancing risk at a time when borrowing costs are elevated. Rising debt obligations could eat into margins if interest rates remain high or if operating cash flows do not improve in the second half of the year.
Despite these financial pressures, Fidson’s growth strategy has enabled it to defy some of the toughest headwinds in Nigeria’s pharmaceutical sector. Industry players have been grappling with currency volatility, rising input costs, and dependence on imported raw materials, which account for more than 70 percent of the country’s pharmaceutical supply chain.
Fidson’s ability to hold margins steady and scale revenues reflects its success in leveraging regional expansion, broadening distribution networks, and adjusting prices in key therapeutic categories. Its geographic diversification across Nigeria and its initial moves into African markets have also positioned it as one of the few domestic players capable of competing at scale.
To sustain this trajectory, Fidson has announced a N30 billion capital raise, aimed at strengthening its balance sheet and financing its next phase of growth. The fundraising is expected to provide a buffer against mounting short-term obligations and offer the resources needed to deepen its presence across Africa.
The success of this capital raise will be closely watched, not only as a measure of investor confidence in Fidson but also as a broader signal for Nigeria’s pharmaceutical sector. With competitors such as May & Baker and Neimeth also navigating similar macroeconomic headwinds, Fidson’s ability to attract new investment could set a precedent for the industry’s financing models.
The pharmaceutical giant’s half-year results highlight both the opportunities and trade-offs in Nigeria’s pharmaceutical landscape. On the one hand, the company has shown that scale, operational efficiency, and strategic expansion can deliver exceptional profits even in a challenging macroeconomic environment. On the other, the rapid build-up of receivables, payables, and borrowings exposes it to liquidity pressures that could quickly erode gains if not managed carefully.
While the company currently remains one of the sector’s standout performers, its long-term resilience will depend on how it navigates the thin line between aggressive growth and financial stability.
